XNAS: QNRX

Download real time

0.24 -0.04 (-14.29%)

New 52W Low today

1.1M XNAS Volume

High volume+loss today

XNAS 28 Mar, 2025 5:30 PM (EDT)

4.9

Market Cap

Low in industry

0.3

Beta 1Year

Very Low volatility

Split

Quoin Pharmaceuticals Ltd - ADR has split the face value of its shares from $1 to $20 on 08 Apr 2025. See details

Insider Trading disclosures for Quoin Pharmaceuticals Ltd - ADR

The latest disclosure was made by Culverwell James Anthony in Quoin Pharmaceuticals Ltd - ADR where a trade of 100,000 Series G Warrants (right to buy) done was reported to US exchanges on Dec. 23, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Culverwell James Anthony	Director	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	100,000	100,000	-		-	Series G Warrants (right to buy)
Denise Carter	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.45 per share.	23 Dec 2024	555,556	602,648	-	0.4	250,000	Ordinary Shares
Anthony James Culverwell	Director	Purchase of securities on an exchange or from another person at price $ 0.45 per share.	23 Dec 2024	100,000	100,317	-	0.5	45,000	Ordinary Shares
Anthony James Culverwell	Director	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	100,000	100,000	-		-	Series F Warrants (right to buy)
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	122,221	122,221	-		-	Series G Warrants (right to buy)
Myers Michael	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.45 per share.	23 Dec 2024	555,556	602,808	-	0.4	250,000	Ordinary Shares
Denise Carter	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	555,556	555,556	-		-	Series G Warrants (right to buy)
Dunn Gordon	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.45 per share.	23 Dec 2024	122,221	151,077	-	0.4	54,999	Ordinary Shares
Myers Michael	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	555,556	555,556	-		-	Series G Warrants (right to buy)
Michael Myers	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	555,556	555,556	-		-	Series F Warrants (right to buy)
Carter Denise	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	555,556	555,556	-		-	Series F Warrants (right to buy)
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	23 Dec 2024	122,221	122,221	-		-	Series F Warrants (right to buy)
Gordon Dunn	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	338,994	338,994	-		-	Share Option (Right to Buy)
Natalie Leong	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	50,714	50,714	-		-	Share Option (Right to Buy)
Denise Carter	Director, Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	536,609	536,609	-		-	Share Option (Right to Buy)
Michael Myers	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	536,603	536,603	-		-	Share Option (Right to Buy)
Anthony James Culverwell	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	50,714	50,714	-		-	Share Option (Right to Buy)
Joseph P. Cooper	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	50,714	50,714	-		-	Share Option (Right to Buy)
Dennis H. Langer	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	50,714	50,714	-		-	Share Option (Right to Buy)
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.78 per share.	09 Sep 2024	4,000	4,856	-	0.8	3,120	Ordinary Shares
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.80 per share.	09 Sep 2024	856	856	-	0.8	685	Ordinary Shares
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.71 per share.	09 Sep 2024	10,000	28,856	-	0.7	7,100	Ordinary Shares
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.91 per share.	09 Sep 2024	10,000	18,856	-	0.9	9,100	Ordinary Shares
Gordon Dunn	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 0.80 per share.	09 Sep 2024	4,000	8,856	-	0.8	3,200	Ordinary Shares
Denise Carter	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.75 per share.	03 Sep 2024	8,825	24,104	-	0.7	6,602	Ordinary Shares
Denise Carter	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.66 per share.	03 Sep 2024	4,100	15,279	-	0.7	2,686	Ordinary Shares
Denise Carter	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.63 per share.	03 Sep 2024	1,822	11,179	-	0.6	1,139	Ordinary Shares
Denise Carter	Director, Chief Operating Officer	Purchase of securities on an exchange or from another person at price $ 0.80 per share.	03 Sep 2024	22,988	47,092	-	0.8	18,310	Ordinary Shares
Michael Myers	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.75 per share.	03 Sep 2024	8,200	23,680	-	0.7	6,134	Ordinary Shares
Michael Myers	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.66 per share.	03 Sep 2024	5,322	15,480	-	0.7	3,490	Ordinary Shares
Michael Myers	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.62 per share.	03 Sep 2024	800	10,158	-	0.6	495	Ordinary Shares
Michael Myers	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 0.80 per share.	03 Sep 2024	23,572	47,252	-	0.8	18,796	Ordinary Shares
Dennis H. Langer	Director	Sale of securities on an exchange or to another person at price $ 0.73 per share.	07 Jun 2024	297	53	-	0.7	217	Ordinary Shares

Showing 1 to 33 of 33 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

New 52W Low today

High volume+loss today

Insider Trading disclosures for Quoin Pharmaceuticals Ltd - ADR

The latest disclosure was made by Culverwell James Anthony in Quoin Pharmaceuticals Ltd - ADR where a trade of 100,000 Series G Warrants (right to buy) done was reported to US exchanges on Dec. 23, 2024.

Screeners based on Insider Trading and SAST parameters